CNS Pharmaceuticals, Inc. (CNSP)
$5.35+3.08%Close
SELLRECOVERY · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3M
- Beta
- 1.02
- P/E (TTM)
- -0.23
- Short % float
- 0.14%
- Days to cover
- 1.0
- SI change
- -69.8%
- 1W
- +0.94%
- 1M
- -6.14%
- vs SPY 1W
- +1.08%
- vs SPY 1M
- -8.65%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 25
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-122.6%
REV YoY-
ROE-204.3%
EPS YoY-
ROA-76.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.23
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.01
P/FCF-
EV/EBITDA0.73
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO5.86
ND/EBITDA-
BETA1.02
Company news
FAQ
- What is LOPJLB’s current signal on CNSP?
- LOPJLB’s latest quantitative signal on CNS Pharmaceuticals, Inc. (CNSP) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is CNSP in?
- CNS Pharmaceuticals, Inc. (CNSP) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does CNS Pharmaceuticals, Inc. (CNSP) do?
- CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of …